| NCT05642455 | SPEARHEAD-3 Pediatric Study | RECRUITING | PHASE1, PHASE2 | 2023-09-01 | 2038-07-30 | 2026-10-01 |
| NCT05601752 | ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-06-26 | 2026-08-12 | 2026-08-12 |
| NCT04752358 | ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | TERMINATED | PHASE2 | 2021-09-15 | 2023-12-15 | 2023-06-09 |
| NCT06048705 | Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer | TERMINATED | PHASE1 | 2021-03-09 | 2023-06-08 | 2023-06-08 |
| NCT04526509 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | TERMINATED | PHASE1 | 2020-12-21 | 2023-06-08 | 2023-06-08 |
| NCT05943990 | Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | TERMINATED | PHASE1 | 2020-12-21 | 2022-10-24 | 2022-10-24 |
| NCT04408898 | SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer | WITHDRAWN | PHASE2 | 2020-07-02 | 2021-12 | 2021-12 |
| NCT06703346 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-12-31 | 2026-07-31 | 2024-03-01 |
| NCT03967223 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-12-31 | 2026-07-31 | 2024-03-01 |
| NCT05993299 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-12-31 | 2025-07-01 | 2022-10-12 |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-08-20 | 2037-04-30 | 2025-12-23 |
| NCT04044768 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-08-13 | 2038-04-01 | 2021-08-29 |
| NCT03391778 | Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | RECRUITING | PHASE1 | 2018-04-09 | 2032-04-01 | 2032-04-01 |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-05-15 | 2032-09 | 2022-12-27 |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-05-08 | 2025-12-07 | 2021-07-07 |
| NCT02989064 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | COMPLETED | PHASE1 | 2016-10 | 2020-06-04 | 2019-12-18 |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | COMPLETED | PHASE1 | 2015-11 | 2021-03-17 | 2020-03-11 |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | TERMINATED | PHASE1, PHASE2 | 2013-10-15 | 2018-04-09 | 2014-12-10 |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | COMPLETED | PHASE1, PHASE2 | 2013-07-09 | 2017-06-06 | 2017-06-06 |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | TERMINATED | PHASE1, PHASE2 | 2011-06-01 | 2018-03-01 | 2016-02-17 |